Entering text into the input field will update the search result below

Science 37: Pioneering Decentralized Clinical Trials

Jan. 02, 2022 3:05 PM ETScience 37 Holdings, Inc. (SNCE)5 Comments


  • Science 37 pioneered the concept of decentralized clinical trials.
  • The Covid-19 pandemic drove more demand for DCTs.
  • The Company is a leader in its niche DCT market worth over $60 billion.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Clear blue aqua marine ocean with turtle and plastic bottle pollution

lindsay_imagery/E+ via Getty Images


Science 37 Holdings, Inc. (NASDAQ:SNCE) is an enabler of universal access to clinical research through its Science 37 Clinical Trial Operating System ('OS), pioneering the concept of decentralized Agile Clinical Trials ('ACTs). To date the Company has executed

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (5)

CR144 Research profile picture
+58% yesterday, but no news.
CR144 Research profile picture
@Avisol Capital Partners : it would be nice to see a new article on Science 37..
CR144 Research profile picture
Feb 2nd 2023 news: Science 37 Holdings announced that it has acquired the life sciences platform from Vault Health, a national leader in remote diagnostics and COVID testing, to further enhance clinical trial workflow orchestration and data interoperability capabilities of the Science 37 platform.

CR144 Research profile picture
@CR144 Research Looking at the recent share price movements: it started moving up a lot since 11th Jan ($0.37) and reached local height on 9th Feb ($0.66) and then it was falling rapidly. Now it is $0.33. So effectively it lost half of its value from its height earlier this month. During that time I see no other news except Feb 2nd acquisition news (as above). 52 week range: ($0.321 - $8.28). Next results (Q4) coming March 6th 2023 - so 1 week from now. Also its worth noting the stock started trading in Nov 2020 at around $10. So effectively the stock totally collapsed since that time having now only $0.33.
BiotechValley Insights profile picture
Seems like a good acquisition target for CROs and tech companies who want to enter this space. Thank you for the excellent analysis.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About SNCE

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SNCE

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.